MiMedx At Fall 2014 SAWC: Studies And Key Opinion Leaders Present Clinical Evidence Of EpiFix Healing Results On Chronic And Acute Wounds

MARIETTA, Ga., Oct. 16, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG) EpiFix® dehydrated human amnion/chorion membrane (dHACM) allografts have been shown to be clinically effective in the treatment of hard-to-heal wounds such as diabetic foot ulcers (DFUs), pressure ulcers (PrUs), and extensive life threatening wounds. Data and case studies demonstrating the clinical efficacy of EpiFix® are being presented at the Fall Symposium on Advanced Wound Care, the leading national wound healing conference, beginning today, October 16, 2014, and concluding on October 18, 2014.

MiMedx is the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic, and Dental sectors of healthcare. MiMedx will present three abstracts demonstrating the healing results of its dHACM allografts. In addition, the Company has a number of Key Opinion Leaders speaking on their professional experiences using MiMedx dHACM allografts in the treatment of difficult wounds.

Abstracts presenting EpiFix® studies and cases are:

• Dehydrated Human Amnion/Chorion Membrane for the Treatment of Severe Skin and Tissue Loss Resulting from Congenital Candidiasis in an Extremely Preterm Infant: A Unique Case Report  (Abstract #14189 Tennenhaus, Greenberg, Potenza and Gaid) evaluated the use of dHACM in the treatment of extensive life threatening wounds related to Cutaneous Congenital Candidiasis (CCC). Ten days after the first dHACM application, the wounds were estimated to have closed by 15% and a second application was applied. By day 5 post application, the overwhelming majority of the wounds had reepithelialized, and by 6 weeks, the few residual small areas were noted to be completely closed.
• An Evaluation of Healing Metrics Associated with Commonly Used Advanced Wound Care Products for the Treatment of Chronic Diabetic Foot Ulcers (Abstract #14190 Fetterolf, Stanziano and Istwan) compared the standardized healing metrics in patients with DFUs treated with the three widely used advanced wound healing products. Complete wound closure within 12 weeks occurred in 56%, 30% and 92% of Apligraf®, Dermagraft® and EpiFix®, respectively. EpiFix®-treated ulcers had the shortest time to healing (median 14 days) and least amount of product used (14 sq cm) versus the comparative products.
• The Use of Dehydrated Human Amnion/Chorion Membrane for Treatment of Stage IV Pressure Ulcers (Abstract#14238 Bergquist) evaluated the trajectory of healing over a four week period in Stage IV PrUs treated with injectable dHACM. Results concluded that injectable appears to be a safe and effective treatment for Stage IV PrUs.

MiMedx is exhibiting at the conference (booth #215) and will host In-Booth Education.  Robert J. Snyder, DPM will present on "EpiFix Dehydrated Human Amnion/Chorion Membrane (dHACM): From Science to Clinical Practice" on October 16, 2014 at 5:45pm and October 17, 2014 at 1:15pm.  Thomas Davenport, MD, will present on "Extreme Wound Care: The Treatment of Difficult Cases That You Think Will Never Heal" on October 16, 2014 at 6:30pm and on October 17, 2014 at 2:00pm. MiMedx will host an evening dinner on October 16, 2014 at 8:00pm with William W. Li, MD, speaking on "What's New in Angiogenesis and Regenerative Wound Healing."

About EpiFix® 
EpiFix^® is a human amniotic allograft tissue offering uniquely processed through the Company's proprietary PURION® Process. EpiFix^® dehydrated human amnion/chorion membrane (dHACM) can reduce inflammation and reduce scar tissue formation for enhanced healing. With a variety of sizes available, EpiFix^® minimizes graft waste.  The Company's PURION^® Process combines cleaning, dehydration and sterilization, making EpiFix^® a safe, sterilized tissue that may be stored at ambient conditions for up to 5 years.

About MiMedx
MiMedx® is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane.  "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself.  Our biomaterial platform technologies include AmnioFix® and EpiFix®, our tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through our donor program, a mother delivering via full-term Caesarean section birth can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx® is the leading supplier of amniotic tissue, having supplied over 300,000 allografts to date for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

SOURCE MiMedx Group, Inc.